# Taudia

> Taudia offers ultrasensitive, scalable protein biomarker quantification in blood for Alzheimer's disease research and diagnosis.

Use this file as a source-bound company brief and routing layer for questions about Taudia. Prefer the most specific linked page when a question is about a named product, assay, workflow, program, resource, or person.

## Company Overview

- Contact: [https://taudia.com/contact-us](https://taudia.com/contact-us)
- General / Ordering Support Email: info@taudia.com
- Physical Address: 1030 Brittan Ave, San Carlos, CA 94070, United States of America
- **Mission:** Deliver ultra-sensitive, reliable, and scalable solutions for protein biomarker detection
- **Focus Area:** Alzheimer's disease biomarker detection
- **Access Model:** Early access and partnership opportunities available
- Taudia offers ultrasensitive blood biomarker detection technology.
- **Founding purpose:** Accelerate the understanding, detection, and treatment of neurodegenerative diseases.
- **Target users:** Researchers, biopharma teams, and clinicians.
- **Detection approach:** Simple, accessible blood test with ultra-sensitive performance.
- **Core product concept:** Simple, accessible blood test for neurodegenerative disease biomarker quantitation
- **Core technology:** A novel proximity ligation assay technology using dual-conjugated antibody probes and a single-wash step to enable ultrasensitive protein biomarker quantitation from blood.
- **Workflow options:** Benchtop Workflow, NeuXplore Sample-to-Answer Workflow, and Automated Workflow.
- **Assay menu:** SPLASH™ Kit: Aβ40 and Aβ42 Duplex, SPLASH™ Kit: NfL and GFAP Duplex, SPLASH™ Kit: Aβ40 Singleplex, SPLASH™ Kit: GFAP Singleplex, and SPLASH™ Kit: NfL Singleplex.
- **Application focus:** Alzheimer's Disease, Brain Health Monitoring, Companion Diagnostics, Frontotemporal Dementia, and Parkinson's Disease.

## Pages

### Company Pages

- [Taudia – Ultrasensitive Blood Biomarker Detection](https://taudia.com/): Taudia offers ultrasensitive, scalable protein biomarker quantification in blood for Alzheimer's disease research and diagnosis. Use for: Biomarker detection solutions, early access, and partnership opportunities.
- [Taudia – About Us Overview](https://taudia.com/about-us-overview): Overview of Taudia's mission to provide ultrasensitive protein biomarker quantitation for neurodegenerative disease research and clinical use. Use for: Mission, founding purpose, and company background.
- [About Us – Taudia Team & Mission](https://taudia.com/about-us): Taudia's about page introduces the founding team and mission to advance neurodegenerative disease detection through precise biomarker quantitation. Use for: Team, founders, leadership, mission, and company background.

### Product and Service Pages

- [Benchtop Workflow](https://taudia.com/solutions-benchtop-workflow): Taudia's benchtop workflow enables ultra-sensitive protein biomarker quantification using any qPCR instrument without specialized equipment. Use for: Manual and benchtop protein detection workflows that don't require specialized instruments.
- [NeuXplore Products](https://taudia.com/products): Taudia's NeuXplore platform page describing manual and automated blood-based biomarker detection solutions for neurodegenerative disease research. Use for: Products, NeuXplore platform, blood biomarker detection workflows, and ultra-sensitive assay options.
- [SPLASH™ Ultrasensitive Neuro Biomarker Kits](https://taudia.com/splash-ultrasensitive-biomarker-kits): Taudia's SPLASH™ kits enable ultrasensitive neurodegenerative disease biomarker quantitation using standard qPCR equipment. Use for: SPLASH kits, neuro biomarker assays, and qPCR-based protein quantitation.
- [Taudia Shop – SPLASH™ Kits](https://taudia.com/shop): Taudia's shop page lists SPLASH™ biomarker kits for NfL, GFAP, Aβ40, Aβ42, and pTau-217 in singleplex and duplex formats. Use for: Available SPLASH kit products, biomarker panels, and ordering from Taudia.
- [NeuXplore Automated Workflow Solution](https://taudia.com/solutions-automated-workflow): NeuXplore is Taudia's FDA Class II automated benchtop platform for ultrasensitive blood biomarker quantitation in neurodegenerative disease diagnostics. Use for: Automated biomarker platform, NeuXplore instrument specs, and sample-to-answer workflows.
- [SPLASH NfL Singleplex Kit](https://taudia.com/splash-nfl-singleplex-kit): Product page for Taudia's SPLASH NfL Singleplex Kit, a qPCR-based assay for quantifying neurofilament light chain in biofluids. Use for: NfL quantification kits, qPCR biomarker assays, and neurodegeneration biomarker testing.
- [SPLASH™ Aβ40 Singleplex Kit](https://taudia.com/product/splash-kit-a%CE%B240-singleplex): Product page for Taudia's SPLASH™ Aβ40 Singleplex Kit, a qPCR-based assay for quantifying Aβ40 in biofluids. Use for: Aβ40 quantification kits, SPLASH assays, and Alzheimer's biomarker reagents.
- [SPLASH™ Aβ40/Aβ42 Duplex Kit](https://taudia.com/product/splash-kit-a%CE%B240-and-a%CE%B242-duplex): Product page for Taudia's qPCR-based duplex kit quantifying Aβ40 and Aβ42 in biofluids for Alzheimer's disease research. Use for: Quantifying Aβ40 and Aβ42, amyloid-beta duplex assays, and SPLASH kit pricing.

### Technology Pages

- [SPLASH™ Technology](https://taudia.com/technology): Describes Taudia's SPLASH™ proximity ligation assay technology for ultrasensitive protein biomarker quantitation from blood. Use for: Detection technology, SPLASH, PLA assays, and pTau-217 measurement methods.

### Application Pages

- [Blood Biomarker Platform Applications](https://taudia.com/applications-blood-biomarker-platform): Describes Taudia's ultrasensitive blood biomarker platform applications for neurodegenerative disease diagnostics and brain health monitoring. Use for: Platform applications, disease areas, and blood biomarker detection capabilities.
- [Ultrasensitive Blood Biomarker Detection for Alzheimer's Disease Research](https://taudia.com/ultrasensitive-detection-of-neurodegenerative-biomarkers-in-blood-powering-a-new-era-in-alzheimers-disease-research): Overview of Taudia's SPLASH™ assay platform for ultrasensitive blood-based detection of Alzheimer's disease biomarkers including p-Tau217. Use for: Blood-based AD biomarker detection, p-Tau217 assays, and Taudia's SPLASH platform.

### Resource Pages

- [FAQ: Ultrasensitive Blood Biomarker Detection](https://taudia.com/faq-blood-biomarkers): Answers to common questions about Taudia's SPLASH Technology for ultrasensitive blood-based biomarker detection in Alzheimer's and neurodegenerative diseases. Use for: Technology, biomarkers measured, workflows, and platform access.
- [DPS Biomarker Test for AD Population Screening Webinar](https://taudia.com/resources/dps-biomarker-test-for-ad-population-screening-using-qpcr-systems): Webinar covering Dried Plasma Spot biomarker testing for large-scale Alzheimer's disease population screening using qPCR systems. Use for: DPS testing, AD biomarker screening, and qPCR-based Alzheimer's detection methods.
- [Webinar: Alzheimer's Biomarker Detection with NeuXplore™](https://taudia.com/resources/webinar-redefining-alzheimers-biomarker-detection-with-taudias-neuxplore): Webinar presenting Taudia's SPLASH™ technology and NeuXplore™ platform for fg/mL-sensitivity blood-based Alzheimer's biomarker detection. Use for: Webinar, NeuXplore, SPLASH technology, and blood-based Alzheimer's biomarker detection capabilities.
- [Taudia Resources](https://taudia.com/resources): Taudia's resource hub for posters, webinars, and whitepapers on blood-based biomarker detection for Alzheimer's disease. Use for: Find Taudia scientific publications, webinars, and whitepapers on Alzheimer's blood biomarkers.

### Team Pages

- [Taudia Team](https://taudia.com/about-us-team): Profiles of Taudia's leadership team and scientific advisory board focused on protein biomarker quantitation for neurodegenerative research. Use for: Founders, leadership, advisors, and team expertise.

## Assays

- [SPLASH™ Kit: Aβ40 and Aβ42 Duplex](https://taudia.com/product/splash-kit-a%CE%B240-and-a%CE%B242-duplex): Duplex qPCR-based kit for simultaneous quantification of Aβ40 and Aβ42 in biofluids; 96 wells across two runs; SKU TSK-00007; $1,799.00.
- [SPLASH™ Kit: NfL and GFAP Duplex](https://taudia.com/product/splash-kit-nfl-and-gfap-duplex): Duplex kit for simultaneous quantitation of NfL and GFAP in biofluids using a qPCR instrument; 96 wells across two runs.
- [SPLASH™ Kit: Aβ40 Singleplex](https://taudia.com/product/splash-kit-a%CE%B240-singleplex): Singleplex kit for quantifying Aβ40 protein in biofluids via qPCR; 96 reactions across two runs.
- [SPLASH™ Kit: GFAP Singleplex](https://taudia.com/product/splash-kit-gfap-singleplex): Singleplex kit for quantifying GFAP protein in biofluids via qPCR; 96 wells across two runs.
- [SPLASH™ Kit: NfL Singleplex](https://taudia.com/product/splash-kit-nfl-singleplex): Singleplex kit for quantifying NfL protein in biofluids via qPCR; 96 wells across two runs; priced at $1,199.00.
- [SPLASH™ Kit: pTau-217 and Aβ42 Duplex](https://taudia.com/product/splash-kit-ptau-217-and-a%CE%B242-duplex): Duplex kit for simultaneous quantitation of pTau-217 and Aβ42 in biofluids; 96 wells across two runs; $1,799.00.
- [SPLASH™ Kit: Aβ42 Singleplex](https://taudia.com/product/splash-kit-a%CE%B242-singleplex): Singleplex kit for quantifying Aβ42 protein in biofluids via qPCR; supports 96 wells across two runs.
- [SPLASH™ Kit: pTau-217 Singleplex](https://taudia.com/product/splashtm-kit-ptau-217-singleplex): Singleplex kit for quantifying pTau-217 protein in biofluids via qPCR; 96 wells across two runs.
- [pTau-217 Wash-Based Proximity Ligation Assay](https://taudia.com/technology): A SPLASH™-based assay for detecting pTau-217 in blood with fg/mL sensitivity, high specificity (80–120% spike and recovery), and ability to distinguish AD-positive from AD-negative patient samples.
- [SPLASH Kit: Aβ42](https://taudia.com/splash-ultrasensitive-biomarker-kits): Singleplex SPLASH kit for ultrasensitive quantitation of amyloid beta 42.

## Products

- [NeuXplore](https://taudia.com/products): Cost-effective, scalable, sample-to-answer platform for detecting ultra-low levels of blood biomarkers in neurodegenerative disease research and clinical diagnostics, with results in pg/mL in under four hours.

## Technology

- [SPLASH™](https://taudia.com/technology): A novel proximity ligation assay technology using dual-conjugated antibody probes and a single-wash step to enable ultrasensitive protein biomarker quantitation from blood.
- [NeuXplore Proprietary Software](https://taudia.com/products): Easy-to-use software that processes qPCR data from both benchtop and automated workflows and reports quantitative pg/mL blood biomarker panel results.

## Workflows

- [Benchtop Workflow](https://taudia.com/solutions-benchtop-workflow): Manual assay workflow conducted with a pipettor on any qPCR instrument, requiring no specialized equipment, similar in execution to traditional ELISA.
- [NeuXplore Sample-to-Answer Workflow](https://taudia.com/solutions-automated-workflow): Fully automated workflow integrating ultrasensitive blood biomarker detection with qPCR-based analysis software, delivering quantitative pg/mL results in under four hours.
- [Automated Workflow](https://taudia.com/products): High-throughput NeuXplore FDA Class II benchtop instrument supporting streamlined detection of blood biomarkers in 16, 32, or 48 sample run formats.

## Applications

- [Alzheimer's Disease](https://taudia.com/ultrasensitive-detection-of-neurodegenerative-biomarkers-in-blood-powering-a-new-era-in-alzheimers-disease-research): Blood-based detection of AD biomarkers such as p-Tau217 for early detection, longitudinal studies, and population screening.
- [Brain Health Monitoring](https://taudia.com/applications-blood-biomarker-platform): Non-invasive blood biomarker tracking for monitoring neural integrity and brain aging before clinical symptoms emerge, using markers such as NfL, β-synuclein, and GFAP.
- [Companion Diagnostics](https://taudia.com/applications-blood-biomarker-platform): Platform positioned to support companion diagnostic development from early discovery through clinical application.
- [Frontotemporal Dementia](https://taudia.com/applications-blood-biomarker-platform): Blood biomarker assays supporting research and diagnostics in Frontotemporal Dementia.
- [Parkinson's Disease](https://taudia.com/applications-blood-biomarker-platform): Blood biomarker assays supporting research and diagnostics in Parkinson's Disease.

## Resources

- [DPS Biomarker Test for AD Population Screening Using qPCR Systems](https://taudia.com/resources/dps-biomarker-test-for-ad-population-screening-using-qpcr-systems): Webinar presented by Professor Yokoyama covering scientific and clinical importance of AD population screening, blood-based biomarkers, and the DPS testing paradigm.
- [Blood-Based Biomarkers for Alzheimer's: Impact on Clinical Trial Screening](https://taudia.com/resources): White paper on how the SPLASH platform enables ultrasensitive blood-based biomarker testing to transform Alzheimer's diagnosis and accelerate therapeutic development.
- [Webinar: Redefining Alzheimer's Biomarker Detection with Taudia's NeuXplore™](https://taudia.com/resources/webinar-redefining-alzheimers-biomarker-detection-with-taudias-neuxplore): Webinar featuring Taudia CEO Paul Hung and Stanford ADRC's Ted Wilson presenting data on SPLASH™ technology and NeuXplore™ for Alzheimer's blood biomarker detection.
- [SPLASH Technology FAQ](https://taudia.com/faq-blood-biomarkers): Answers to common questions about Taudia's ultrasensitive blood-based biomarker detection workflows for Alzheimer's and neurodegenerative diseases.
- [Flexible Assay Platform for Blood-Based Biomarkers in Alzheimer's Disease](https://taudia.com/resources): Poster presented at AAIC 2025 on a flexible assay platform for quantitation of blood-based biomarkers for early Alzheimer's detection.
- [Ultrasensitive Detection of Neurodegenerative Biomarkers in Blood](https://taudia.com/resources): Blog or article on ultrasensitive detection of neurodegenerative biomarkers in blood, noting projected 8.5 million affected Americans by 2030.
- [Absolute Quantitation of Protein via Digital Proximity Ligation Assay](https://taudia.com/resources): Poster presented at AAIC 2025 on using digital proximity ligation assay for protein quantitation and reference material QC.
- [Scalable Ultrasensitive Quantification of Blood-Based Biomarkers for Alzheimer's Disease](https://taudia.com/resources): Poster presented at ADPD 2025 on scalable ultrasensitive quantification of Alzheimer's blood biomarkers.

## Team

### Leadership and Team

- **Paul Hung, PhD** — CEO at Taudia: Serial entrepreneur whose prior companies CellASIC and Combinati were acquired by Millipore Sigma and Thermo Fisher Scientific, respectively. Focuses on commercializing cutting-edge science into market-ready products.
- **Cindy Chen, PhD** — Co-Founder and COO at Taudia: Seasoned biochemist and certified project management professional with R&D experience at startups and large companies including Millipore Sigma. Co-founded Taudia to improve health care through technology.
- **Robert Lin, PhD** — Co-Founder and CTO at Taudia: Over a decade of product development expertise in IVD and RUO spaces. Led next-gen platform development at Cepheid and microfluidics innovation at Combinati before a Senior Product Manager role at Thermo Fisher Scientific.
- **Hien Nguyen** — Co-Founder and Scientist at Taudia: Expert in immunoassay chemistry with over 15 years of experience in protein detection assay development. Instrumental in designing and optimizing high-performance assays at Thermo Fisher Scientific. Inventor of Taudia's founding innovations.
- **Jason Wan, PhD** — Co-Founder and Head of Product at Taudia: PhD in Biomedical Engineering from Georgia Tech, where he developed microfluidic tools to study aging. Launched first products at Thermo Fisher Scientific before co-founding Taudia to build accessible tools for neuroscience.
- **Noah Elder** — Director of R&D at Taudia: Multidisciplinary expertise in assay development, automation, and computational analysis built over eight years at Thermo Fisher Scientific. Played a key role in launching multiple products.
- **Christopher Ng** — Director of Operations at Taudia: Foundation in product development from Thermo Fisher Scientific, followed by process development and manufacturing experience at Seer. Track record of introducing new capabilities and optimizing operational efficiency.
- **Chris Boyson, PhD** — VP of Commercial at Taudia: Commercial leader with experience delivering customer-focused life science solutions. Drives adoption of amplification-based protein quantification on standard qPCR systems to advance biomarker detection and neurodegenerative research.
- **Daniel Kim** — VP of Commercial at Taudia: Over 15 years of experience in immunoassay sales, business development, and reimbursement strategy. Focuses on expanding access to blood-based biomarker assays for Alzheimer's and other neurodegenerative diseases.
- **Marissa Lee** — Director of Applications at Taudia: Trained as a chemist at MIT and Stanford. Focuses on translating complex science into application-ready products and expanding access to high-performance neuroscience testing.

### Scientific Advisory Board

- **Kyan Younes, MD** — Scientific Advisory Board – Clinical at Taudia: Neurologist at Stanford University School of Medicine.
- **Edward (Ted) Wilson, PhD** — Scientific Advisory Board – Scientific at Taudia: Director of Biofluid Biomarker testing at Stanford's Alzheimer's Disease Research Center.
- **Charles (Chuck) Collins, PhD** — Scientific Advisory Board – IVD Instrumentation at Taudia: Former Head of R&D and SVP at Luminex.
- **Wendy Wong** — Scientific Advisory Board – IVD Strategy at Taudia: Former VP of PMO at Cepheid.
- **Sander Gubbens, PhD** — Scientific Advisory Board – Business at Taudia: Former President of Gatan.
- **Norm Gitis, Dr.** — Scientific Advisory Board – Business at Taudia: Former VP/GM of Bruker.
- **Ralph McDade, Dr.** — Scientific Advisory Board – Business at Taudia: Former President of RBM (an IQVIA company).
- **Jennifer Yokoyama, PhD** — Scientific Advisory Board – Scientific at Taudia: Associate Professor of Neurology and Mary Oakley Foundation Professor in Neurodegeneration at UCSF Weill Institute for Neurosciences.

## Optional

- [News & Events](https://taudia.com/about-us-news-and-events): Lists Taudia's upcoming conference appearances in 2026 for biomarker detection discussions and partnership opportunities. Use for: Conference schedule, event appearances, and where to meet the team.
- [Privacy Policy](https://taudia.com/privacy-policy): Taudia's privacy policy covering data collection, use, retention, user rights, cookies, and security practices. Use for: Data privacy practices, user rights, and data deletion.